Clinical leadership IN8bio is a clinical-stage biopharma focused on gamma-delta T cell therapies with ongoing data in glioblastoma and planned expansion into autoimmune indications, presenting multiple collaboration and outsourcing opportunities with CROs, academic partners, and pharma licensors seeking specialized γδ T cell platforms.

DeltEx platform The DeltEx platform combines ex vivo-expanded γδ T cells with genetic engineering and cell-type specific manufacturing, enabling potential partnerships for custom cell therapy development, process optimization services, and transfer of manufacturing capabilities to partner sites.

Strategic milestones Recent peer‑reviewed results in glioblastoma and the appointment of senior R&D leadership signal readiness for broader clinical programs and potential licensing of data or co-development deals with larger biotech or pharma companies seeking validated γδ T cell assets.

Financial scale With revenue in the mid tens of millions and total funding around ninety-three million, IN8bio may be seeking strategic collaborations, milestone-based co-development funding, or manufacturing partnerships to accelerate pipeline progression and expand clinical trial capacity.

Investor outreach Ongoing investor activity and conference participation, including Nasdaq-focused events and inducement stock option programs, indicate openness to partnerships with strategic investors or corporate venture arms seeking early-stage cell therapy assets and potential equity-backed collaboration deals.